In vivo, a DSS-induced IBD mouse model was used to assess intestinal pathology, inflammation, and RNF31-TFEB-NLRP3 axis proteins after treatment with a novel synthetic curcumin analog (CM-C1). Here, NLRP3 is linked to inflammatory bowel disease.